Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha, China.
Cardiovasc Drugs Ther. 2011 Oct;25(5):469-76. doi: 10.1007/s10557-011-6335-3.
Obesity is one of the most common lifestyle-related diseases. Being closely associated with insulin resistance, hypertension and dyslipidemia, it is also a component of metabolic syndrome and is involved in the development of atherosclerosis and cardiovascular and renal ailments. Obesity is also accompanied with a state of chronic inflammation. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a receptor for oxidized low density lipoprotein (ox-LDL), is expressed not only in endothelial cells, but also in macrophages, vascular smooth muscle cells, platelets and adipocytes. LOX-1 binds multiple ligands, has diverse physiological functions and plays a critical role in the signal transduction. It may well turn out to be a key, or very important, factor in the development of hypertension, diabetes mellitus and hyperlipidemia, the most important risk factors for atherosclerosis. In recent studies, LOX-1 upregulation appears to be a vital factor in obesity and its complications. This review summarizes current knowledge of obesity and the relationship between LOX-1 and obesity.
肥胖是最常见的与生活方式相关的疾病之一。它与胰岛素抵抗、高血压和血脂异常密切相关，也是代谢综合征的组成部分，参与动脉粥样硬化和心血管及肾脏疾病的发生。肥胖还伴随着慢性炎症状态。凝集素样氧化低密度脂蛋白受体-1（LOX-1）是氧化低密度脂蛋白（ox-LDL）的受体，不仅在血管内皮细胞中表达，也在巨噬细胞、血管平滑肌细胞、血小板和脂肪细胞中表达。LOX-1 结合多种配体，具有多种生理功能，在信号转导中起着关键作用。它很可能成为高血压、糖尿病和高血脂症（动脉粥样硬化最重要的危险因素）发展的关键或非常重要的因素。在最近的研究中，LOX-1 的上调似乎是肥胖及其并发症的一个重要因素。本文综述了肥胖和 LOX-1 与肥胖之间关系的最新知识。
